ZA200803488B - GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance - Google Patents

GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance

Info

Publication number: ZA200803488B
Authority: ZA; South Africa
Prior art keywords: glp; peptide; component; sequence; glucagon
Prior art date: 2005-09-22

Application number

ZA200803488A

Other languages

English (en)

Inventor

Geigle Peter

Wallrapp Christine

Thoenes Eric

Original Assignee

Uk Biocompatibles Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2006-09-22

Publication date

2009-10-28

2006-09-22 Application filed by Uk Biocompatibles Ltd filed Critical Uk Biocompatibles Ltd

2009-10-28 Publication of ZA200803488B publication Critical patent/ZA200803488B/xx

Links

102400000322 Glucagon-like peptide 1 Human genes 0.000 title abstract 6
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 6
108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
230000004927 fusion Effects 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 title 2
102000035195 Peptidases Human genes 0.000 title 1
108091005804 Peptidases Proteins 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
235000019833 protease Nutrition 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
208000034615 apoptosis-related disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07F—COIN-FREED OR LIKE APPARATUS
- G07F11/00—Coin-freed apparatus for dispensing, or the like, discrete articles
- G07F11/02—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines
- G07F11/04—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines in which magazines the articles are stored one vertically above the other
- G07F11/16—Delivery means
- G07F11/165—Delivery means using xyz-picker or multi-dimensional article picking arrangements

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ZA200803488A 2005-09-22 2006-09-22 GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance ZA200803488B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05020718A EP1767545B1 (de)	2005-09-22	2005-09-22	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz

Publications (1)

Publication Number	Publication Date
ZA200803488B true ZA200803488B (en)	2009-10-28

Family

ID=35700191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200803488A ZA200803488B (en)	2005-09-22	2006-09-22	GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance

Country Status (23)

Country	Link
US (2)	US8431533B2 (de)
EP (5)	EP2045265B1 (de)
JP (2)	JP5222729B2 (de)
KR (1)	KR20080064840A (de)
CN (1)	CN101273058A (de)
AT (1)	ATE448247T1 (de)
AU (1)	AU2006299134B2 (de)
BR (1)	BRPI0616107A2 (de)
CA (1)	CA2619053A1 (de)
CY (1)	CY1109778T1 (de)
DE (1)	DE602005017628D1 (de)
DK (1)	DK1767545T3 (de)
EA (1)	EA013796B1 (de)
ES (3)	ES2397289T3 (de)
HR (1)	HRP20100062T1 (de)
IL (1)	IL188904A0 (de)
PL (1)	PL1767545T3 (de)
PT (1)	PT1767545E (de)
RS (1)	RS51319B (de)
SG (1)	SG165414A1 (de)
SI (1)	SI1767545T1 (de)
WO (1)	WO2007039140A1 (de)
ZA (1)	ZA200803488B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
EP1948676A4 (de) *	2005-10-27	2011-05-25	Peptron Co Ltd	Biologisch wirksames substanz-protein-konjugat und stabilisierung einer biologisch aktiven substanz damit
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
ATE444741T1 (de)	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP1972349A1 (de) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
EP2163243A1 (de) *	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
CN101993485B (zh)	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
RU2584572C2 (ru) *	2010-02-11	2016-05-20	Ф.Хоффманн-Ля Рош Аг	Способ получения полипептида, конъюгированного с поли(этиленгликолевым) фрагментом, нуклеиновая кислота и слитый полипептид, предназначенные для применения в способе
WO2012043397A1 (ja) *	2010-10-01	2012-04-05	株式会社エム・エム・ティー	イミュノグロブリン結合能を有するペプチド
CN102766204B (zh) *	2011-05-05	2014-10-15	天津药物研究院	胰高血糖素样肽-1突变体多肽及其制备方法和其应用
CN102363633B (zh) *	2011-11-16	2013-11-20	天津拓飞生物科技有限公司	胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
JP6525456B2 (ja)	2012-11-20	2019-06-05	メデリスダイアビーティーズ，エルエルシー	インスリン抵抗性のための改善されたペプチド製剤
CN104371019B (zh) *	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104707131A (zh) *	2013-12-13	2015-06-17	上海建华精细生物制品有限公司	一种药物组合物及其制备方法和用途
NZ726623A (en)	2014-05-28	2020-02-28	Mederis Diabetes Llc	Improved peptide pharmaceuticals for insulin resistance
AU2016218759B2 (en)	2015-02-11	2021-11-25	Gmax Biopharm Llc.	Stabilized solution preparation of pharmaceutical GLP-1R antibody fusion protein
KR101661332B1 (ko) *	2015-05-28	2016-09-29	(의료)길의료재단	글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
JP7026044B2 (ja)	2015-12-23	2022-02-25	ザ・ジョンズ・ホプキンス・ユニバーシティー	神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ－１ｒアゴニスト
CN107818433B (zh) *	2016-09-14	2022-07-05	菜鸟智能物流控股有限公司	取件方法、物流信息处理方法及装置、系统
WO2018104558A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
AU2017371516C1 (en) *	2016-12-09	2021-09-02	Zealand Pharma A/S	Acylated GLP-1/GLP-2 dual agonists
CN108341880B (zh) *	2017-01-23	2023-07-04	天津药物研究院有限公司	含有胰高血糖素样肽-1和胰高血糖素的片段类似物的嵌合多肽及其用途
KR101827245B1 (ko) *	2017-12-26	2018-02-08	(주)제이유타이드	알라린을 주성분으로 하는 요독증 치료제
PL3735295T4 (pl)	2018-01-03	2025-01-20	Mederis Diabetes, Llc	Ulepszone farmaceutyki peptydowe do leczenia nash i innych zaburzeń
KR101903564B1 (ko) *	2018-01-31	2018-11-13	한국지질자원연구원	제지공정에서 발생되는 부산물의 재활용 방법
HRP20240749T1 (hr)	2018-04-05	2024-09-13	Sun Pharmaceutical Industries Limited	Novi analozi glp-1
BR112021011595A2 (pt)	2018-12-21	2021-11-30	Jiangsu Hengrui Medicine Co	Proteína biespecífica
KR102349717B1 (ko) *	2020-03-12	2022-01-11	주식회사 에스엘메타젠	신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
US20240368239A1 (en) *	2020-03-12	2024-11-07	Sl Metagen	Novel bispecific protein and use thereof
WO2022015039A1 (ko) *	2020-07-14	2022-01-20	(주)지아이이노베이션	글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
EP4252780A1 (de) *	2020-11-27	2023-10-04	D&D Pharmatech Inc.	Biologisch aktives konjugat mit biotinteil, fettsäureteil oder kombination davon, die daran gekoppelt sind
AU2021385222B2 (en) *	2020-11-27	2025-05-29	D&D Pharmatech Inc.	Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
US12171806B2 (en)	2021-09-28	2024-12-24	Spitfire Pharma Llc	Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
CN112661862B (zh) *	2020-12-25	2023-03-31	深圳大学	一种融合蛋白及其制备方法和应用
CN113846124A (zh) *	2021-09-26	2021-12-28	康霖生物科技（杭州）有限公司	一种用于糖代谢相关疾病基因治疗的核酸构建体
CN115850438B (zh) *	2021-12-28	2023-05-12	北京惠之衡生物科技有限公司	一种长效glp-1衍生物
CN115920004A (zh) *	2022-11-11	2023-04-07	深圳市图微安创科技开发有限公司	药物组合物及其制备方法
JPWO2024135375A1 (de)	2022-12-22	2024-06-27
WO2024144431A1 (ru) *	2022-12-29	2024-07-04	Авва Фармасьютикалс Лтд	Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
WO2025005743A1 (ko) *	2023-06-30	2025-01-02	주식회사 휴온스랩	Glp 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US586128A (en) *		1897-07-13		Toilet-paper holder
US4352883A (en) *	1979-03-28	1982-10-05	Damon Corporation	Encapsulation of biological material
ATE6548T1 (de) *	1979-10-16	1984-03-15	Winfried Dr. Med. Stoecker	Vorrichtung zur durchfuehrung von mikroanalysen.
US4596792A (en)	1981-09-04	1986-06-24	The Regents Of The University Of California	Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja)	1982-08-30	1984-03-02	Musashi Eng Kk	紙葉判別方法
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
DD224119A1 (de)	1983-11-07	1985-06-26	Univ Schiller Jena	Temperierbarer probentraeger
US4599231A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en)	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US5116943A (en)	1985-01-18	1992-05-26	Cetus Corporation	Oxidation-resistant muteins of Il-2 and other protein
US4601903A (en)	1985-05-01	1986-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5144139A (en) *	1985-08-05	1992-09-01	Biotrack, Inc.	Capillary flow device
US4687529A (en) *	1985-08-30	1987-08-18	Miles Laboratories, Inc.	Method of making a reagent test device containing hydrophobic barriers
CA1292176C (en)	1985-09-18	1991-11-19	Joel M. Blatt	Volume metering capillary gap device for applying a liquid sample onto a reactive surface
US5017691A (en)	1986-07-03	1991-05-21	Schering Corporation	Mammalian interleukin-4
US6849708B1 (en) *	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
ATE138102T1 (de) *	1991-02-19	1996-06-15	Takeda Chemical Industries Ltd	Verfahren zur herstellung von cysteinfreien peptiden
CA2062338A1 (en)	1991-03-15	1992-09-16	Zia Yassinzadeh	Electronic control cartridge and method of simulating light transmission patterns
GB9311147D0 (en)	1993-05-28	1993-07-14	Long Ashton Research Station	Regulation of plant growth
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
BE1008987A3 (fr)	1995-01-06	1996-10-01	Robyn Pierre	Blocs refractaires a canalisations pour sols de fours verriers et installation dans les sols de circuits de refroidissement ou de chauffage, permettant d'ameliorer le controle thermique des sols et la qualite du verre.
JP3643863B2 (ja)	1995-08-09	2005-04-27	アークレイ株式会社	液体保持具とその製造方法
PL187095B1 (pl)	1996-03-01	2004-05-31	Novo Nordisk As	Peptyd, kompozycja farmaceutyczna zawierająca peptyd, zastosowanie peptydu oraz zastosowanie frakcji HPLC ekstraktu nowotworu glukagonoma
US6165739A (en) *	1996-03-13	2000-12-26	Compucyte Corporation	Multiple simultaneous testing media
EP2016950B1 (de) *	1996-08-08	2011-01-05	Amylin Pharmaceuticals, Inc.	Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
ES2283025T3 (es)	1996-08-30	2007-10-16	Novo Nordisk A/S	Derivados de glp-1.1.
WO1998020895A1 (en)	1996-11-12	1998-05-22	Novo Nordisk A/S	Use of glp-1 peptides
CA2318379A1 (en)	1998-01-12	1999-07-15	Betagene, Inc.	Identification of substances that modify cellular secretory function
DE69938100D1 (de) *	1998-03-06	2008-03-20	Spectrx Inc	Integrierte porations-, sammel- und analysevorrichtung und verfahren dafür
EP1950224A3 (de)	1998-03-09	2008-12-17	Zealand Pharma A/S	Pharmakologisch aktive Peptidkonjugate mit verringerter enzymatischer Hydrolysetendenz
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6267954B1 (en) *	1999-11-24	2001-07-31	Universite De Paris V Rene-Descartes	Intraocular transplantation of encapsulated cells
US6706159B2 (en) *	2000-03-02	2004-03-16	Diabetes Diagnostics	Combined lancet and electrochemical analyte-testing apparatus
AU2001237254A1 (en)	2000-03-08	2001-09-17	Novo-Nordisk A/S	Lowering serum lipids
DE10039643A1 (de) *	2000-08-14	2002-02-28	Max Planck Gesellschaft	Funktionalisierte Perylentetracarbonsäurediimide
CN1483041A (zh) *	2000-12-07	2004-03-17		Glp-1融合蛋白
US6821485B2 (en)	2001-02-09	2004-11-23	Wisconsin Alumni Research Foundation	Method and structure for microfluidic flow guiding
JP4689144B2 (ja)	2001-02-22	2011-05-25	ノバルティスアーゲー	眼球血管新生を処置するための方法
US20030034147A1 (en) *	2001-05-31	2003-02-20	Houck Glenn M.	Apparatus which eliminates the need for idling by trucks
DK1412384T3 (da)	2001-06-28	2008-04-28	Novo Nordisk As	Stabil formulering af modificeret GLP-1
CN1363654A (zh)	2001-07-19	2002-08-14	上海华谊生物技术有限公司	生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
WO2003010305A1 (en)	2001-07-27	2003-02-06	Arhus Amt	Immortilized stem cells
ATE408414T1 (de)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
US20040143104A1 (en) *	2001-08-08	2004-07-22	Wadsworth Samuel C.	Methods of treating diabetes and other blood sugar disorders
US7238663B2 (en)	2001-08-28	2007-07-03	Eli Lilly And Company	Pre-mixes of GLP-1 and basal insulin
US7176278B2 (en) *	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US7166208B2 (en) *	2004-03-03	2007-01-23	Stephen Eliot Zweig	Apoenzyme reactivation electrochemical detection method and assay
ATE352312T1 (de) *	2001-12-29	2007-02-15	Novo Nordisk As	Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
JP4282485B2 (ja) *	2002-01-08	2009-06-24	イーライリリーアンドカンパニー	伸長グルカゴン様ペプチド−１アナログ
GB2388898B (en)	2002-04-02	2005-10-05	Inverness Medical Ltd	Integrated sample testing meter
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20030143113A2 (en) *	2002-05-09	2003-07-31	Lifescan, Inc.	Physiological sample collection devices and methods of using the same
CA2497794A1 (en)	2002-09-06	2004-03-18	Bayer Pharmaceuticals Corporation	Modified glp-1 receptor agonists and their pharmacological methods of use
JP4548335B2 (ja) *	2003-03-07	2010-09-22	味の素株式会社	腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
US6969166B2 (en)	2003-05-29	2005-11-29	3M Innovative Properties Company	Method for modifying the surface of a substrate
US7057116B2 (en)	2003-06-02	2006-06-06	Intel Corporation	Selective reference plane bridge(s) on folded package
DK1641823T3 (da) *	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1-analog fusionsproteiner
EP1498143A1 (de)	2003-07-18	2005-01-19	Aventis Pharma S.A.	Selbstemulgierende und selbstmicroemulgierende Formulierungen zur oralen Verabreichung von Taxoiden
WO2005014049A2 (en)	2003-08-08	2005-02-17	Novo Nordisk A/S	Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
EP1677819A1 (de)	2003-10-10	2006-07-12	Novo Nordisk A/S	Moleküle mit langzeitwirkung in formulierungen mit verzögerter freisetzung
CN101665538A (zh) *	2003-12-18	2010-03-10	诺沃挪第克公司	与白蛋白样物质相连的新glp-1类似物
WO2005072216A2 (en)	2004-01-20	2005-08-11	The Curators Of The University Of Missouri	Supported molecular biofluid viscosity sensors for in vitro and in vivo use
CN1961000B (zh)	2004-02-11	2011-05-04	安米林药品公司	具有可选择特性的杂合多肽
DE602004011688D1 (de)	2004-03-05	2008-03-20	Egomedical Swiss Ag	Analyttestsystem zur bestimmung der konzentration eines analyten in einer physiologischen flüssigkeit
KR20070004078A (ko)	2004-03-31	2007-01-05	센토코 인코포레이티드	인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
WO2006010143A2 (en) *	2004-07-13	2006-01-26	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
BRPI0419004A (pt)	2004-08-13	2007-12-11	Egomedical Technologies Ag	sistema de testes de analitos para determinar a concentração de um analito em um fluido fisiológico ou aquoso
US7442682B2 (en) *	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
US20090175795A1 (en)	2005-07-29	2009-07-09	Amprotein Corporation	Chimeric therapeutic agents
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
ATE444741T1 (de) *	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP1972349A1 (de) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2163243A1 (de)	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern

2005
- 2005-09-22 DE DE602005017628T patent/DE602005017628D1/de active Active
- 2005-09-22 EP EP08021837A patent/EP2045265B1/de active Active
- 2005-09-22 RS RSP-2010/0039A patent/RS51319B/sr unknown
- 2005-09-22 DK DK05020718.2T patent/DK1767545T3/da active
- 2005-09-22 PT PT05020718T patent/PT1767545E/pt unknown
- 2005-09-22 PL PL05020718T patent/PL1767545T3/pl unknown
- 2005-09-22 SI SI200530887T patent/SI1767545T1/sl unknown
- 2005-09-22 AT AT05020718T patent/ATE448247T1/de active
- 2005-09-22 ES ES08021837T patent/ES2397289T3/es active Active
- 2005-09-22 EP EP05020718A patent/EP1767545B1/de active Active
- 2005-09-22 ES ES05020718T patent/ES2336575T3/es active Active
2006
- 2006-09-22 EP EP10009718A patent/EP2261245A1/de not_active Withdrawn
- 2006-09-22 WO PCT/EP2006/009226 patent/WO2007039140A1/en active Application Filing
- 2006-09-22 BR BRPI0616107-3A patent/BRPI0616107A2/pt not_active IP Right Cessation
- 2006-09-22 EA EA200800699A patent/EA013796B1/ru not_active IP Right Cessation
- 2006-09-22 CN CNA2006800350367A patent/CN101273058A/zh active Pending
- 2006-09-22 EP EP06792228A patent/EP1926748B1/de not_active Not-in-force
- 2006-09-22 US US11/991,562 patent/US8431533B2/en not_active Expired - Fee Related
- 2006-09-22 EP EP09014513A patent/EP2174952A3/de not_active Withdrawn
- 2006-09-22 AU AU2006299134A patent/AU2006299134B2/en not_active Ceased
- 2006-09-22 SG SG201006921-9A patent/SG165414A1/en unknown
- 2006-09-22 ZA ZA200803488A patent/ZA200803488B/xx unknown
- 2006-09-22 JP JP2008531616A patent/JP5222729B2/ja not_active Expired - Fee Related
- 2006-09-22 ES ES06792228T patent/ES2394218T3/es active Active
- 2006-09-22 CA CA002619053A patent/CA2619053A1/en not_active Abandoned
- 2006-09-22 KR KR1020087009543A patent/KR20080064840A/ko not_active Ceased
2008
- 2008-01-21 IL IL188904A patent/IL188904A0/en unknown
2010
- 2010-02-02 HR HR20100062T patent/HRP20100062T1/hr unknown
- 2010-02-11 CY CY20101100139T patent/CY1109778T1/el unknown
2012
- 2012-05-29 US US13/482,354 patent/US8853159B2/en not_active Expired - Fee Related
2013
- 2013-01-25 JP JP2013012558A patent/JP2013099352A/ja active Pending

Also Published As

Publication number	Publication date
PL1767545T3 (pl)	2010-04-30
JP2009508505A (ja)	2009-03-05
AU2006299134B2 (en)	2012-02-23
PT1767545E (pt)	2010-02-05
SI1767545T1 (sl)	2010-03-31
EP1926748B1 (de)	2012-08-29
ATE448247T1 (de)	2009-11-15
DE602005017628D1 (de)	2009-12-24
JP5222729B2 (ja)	2013-06-26
EP2174952A2 (de)	2010-04-14
WO2007039140A1 (en)	2007-04-12
BRPI0616107A2 (pt)	2011-06-07
HRP20100062T1 (hr)	2010-03-31
ES2394218T3 (es)	2013-01-23
EP1926748A1 (de)	2008-06-04
US20110130329A1 (en)	2011-06-02
HK1129121A1 (en)	2009-11-20
ES2397289T3 (es)	2013-03-06
IL188904A0 (en)	2008-04-13
US8853159B2 (en)	2014-10-07
EP2045265A1 (de)	2009-04-08
EP2261245A1 (de)	2010-12-15
SG165414A1 (en)	2010-10-28
RS51319B (sr)	2010-12-31
US8431533B2 (en)	2013-04-30
EA200800699A1 (ru)	2008-10-30
EP1767545A1 (de)	2007-03-28
AU2006299134A1 (en)	2007-04-12
ES2336575T3 (es)	2010-04-14
EP1767545B1 (de)	2009-11-11
US20120238497A1 (en)	2012-09-20
KR20080064840A (ko)	2008-07-09
CN101273058A (zh)	2008-09-24
CY1109778T1 (el)	2014-09-10
EA013796B1 (ru)	2010-06-30
CA2619053A1 (en)	2007-04-12
EP2174952A3 (de)	2010-11-17
JP2013099352A (ja)	2013-05-23
DK1767545T3 (da)	2010-03-15
EP2045265B1 (de)	2012-11-21

Publication	Publication Date	Title
ZA200803488B (en)	2009-10-28	GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2008116648A3 (en)	2008-12-31	Novel glp-1 fusion peptides, their production and use
JP5580784B2 (ja)	2014-08-27	選択可能な特性を有するハイブリッドポリペプチド
ES2225107T3 (es)	2005-03-16	Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes.
US20190085043A1 (en)	2019-03-21	Fusion proteins for treating a metabolic syndrome
TW200716679A (en)	2007-05-01	N-terminally modified GLP-1 receptor modulators
EP2390264A1 (de)	2011-11-30	GIP-Analog und Hybridpolypeptide mit auswählbaren Eigenschaften
WO2007140284A3 (en)	2008-12-31	N-terminally modified glp-1 receptor modulators
EP2926825A1 (de)	2015-10-07	Therapeutika mit elastinähnlichen peptiden
WO2006014287A8 (en)	2006-05-26	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20050137135A1 (en)	2005-06-23	Novel analogues of glucose-dependent insulinotropic polypeptide
GB2431583A (en)	2007-05-02	Combination therapy using transferrin fusion proteins comprising GLP-1
EP2301962A3 (de)	2011-11-02	Erfindung betreffend GLP-1 und Exendin
WO2004094461A3 (en)	2005-09-15	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2006086727A3 (en)	2006-11-02	Treating diabetes with glucagon-like peptide-1 secretagogues
JP2004509079A5 (de)	2005-08-18
WO2006121860A3 (en)	2007-04-12	Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2010013012A3 (en)	2010-04-01	Hypothermia inducing polypeptides and uses thereof
WO2007082264A3 (en)	2007-12-21	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20110288001A1 (en)	2011-11-24	Biologically active proteins activatable by peptidase
JP2014527405A (ja)	2014-10-16	作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CN101155828A (zh)	2008-04-02	Gip类似物和具有可选择性质的杂合多肽
Linderoth et al.	2021	GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity